专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013168108A2 CHEMOKINE RECEPTOR BINDING POLYPEPTIDES 审中-公开
标题翻译：化合物受体结合多肽
公开(公告)号：WO2013168108A2
公开(公告)日：2013-11-14
申请号：PCT/IB2013/053711
申请日：2013-05-08
申请人： NOVARTIS AG , BROWN, Zarin , BRADLEY, Michelle , CHARLTON, Steven John , VAN HEEKE, Gino Anselmus , CROMIE, Karen , DOMBRECHT, Bruno , STEFFENSEN, Soren , BAUMEISTER, Judith , BOUCHE, Marie-Paule , BOUTTON, Carlo , BUYSE, Marie-Ange , SNOECK, Veerle , STAELENS, Stephanie
发明人： BROWN, Zarin , BRADLEY, Michelle , CHARLTON, Steven John , VAN HEEKE, Gino Anselmus , CROMIE, Karen , DOMBRECHT, Bruno , STEFFENSEN, Soren , BAUMEISTER, Judith , BOUCHE, Marie-Paule , BOUTTON, Carlo , BUYSE, Marie-Ange , SNOECK, Veerle , STAELENS, Stephanie
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/468 , C07K2317/22 , C07K2317/31 , C07K2317/34 , C07K2317/35 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/31
摘要： The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
摘要翻译：本发明涉及针对或特异性结合趋化因子受体CXCR2的多肽，特别涉及能够调节CXCR2信号转导的多肽。本发明还涉及能够表达本发明多肽的核酸，载体和宿主细胞，包含多肽的药物组合物以及用于治疗涉及CXCR2异常功能的疾病的所述多肽和组合物的用途。

2. 发明申请

WO2012175741A2 TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS 审中-公开
标题翻译：涉及免疫球蛋白单个可变区域的测定中预测，检测和降低相关蛋白质干扰的技术
公开(公告)号：WO2012175741A2
公开(公告)日：2012-12-27
申请号：PCT/EP2012/062251
申请日：2012-06-25
申请人： ABLYNX NV , BAUMEISTER, Judith , BOUCHE, Marie-Paule, Lucienne, Armanda , BOUTTON, Carlo , BUYSE, Marie-Ange , SNOECK, Veerle , STAELENS, Stephanie
发明人： BAUMEISTER, Judith , BOUCHE, Marie-Paule, Lucienne, Armanda , BOUTTON, Carlo , BUYSE, Marie-Ange , SNOECK, Veerle , STAELENS, Stephanie
IPC分类号： C07K16/00
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/00 , C07K16/2875 , C07K16/42 , C07K16/4283 , C07K2317/22 , C07K2317/31 , C07K2317/35 , C07K2317/567 , C07K2317/569 , C07K2317/92 , C07K2317/94 , C07K2319/30 , G01N33/5306 , G01N33/6854
摘要： This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; - methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; - modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.
摘要翻译：本发明提供并且在某些特定但非限制性方面涉及：可用于预测给定ISV是否将如本文所述受到蛋白质干扰和/或产生（特异性）信号的测定法测定（例如在ADA免疫测定中）。这样的预测测定可以例如用于测试给定的ISV是否可能具有引起这种蛋白质干扰和/或这种信号的倾向; 选择不是或不太容易发生蛋白质干扰的ISV或给出这样的信号; 作为可用于测试对ISV的某些修改（完全或部分）是否降低其引起这种干扰或这种信号的趋势的测定或测试; 和/或作为可用于指导ISV的修饰或改进的测定或测试，以便减少引起这种蛋白质干扰或信号的趋势; - 修改和/或改进ISV以消除或减少其引起这种蛋白质干扰或这种信号的趋势的方法; - 可以引入到ISV中的修饰，其去除或减少引起这种蛋白质干扰或这种信号的趋势; 已经特别选择的ISV（例如，使用本文所述的测定）具有没有或低（呃）/降低的引起这种蛋白质干扰或这种信号的倾向; 修饰和/或改进的ISV，其没有或低（呃）/降低的趋势引起这种蛋白质干扰或这种信号。

3. 发明申请

WO2017087589A3 PD1 AND/OR LAG3 BINDERS 审中-公开
公开(公告)号：WO2017087589A3
公开(公告)日：2017-05-26
申请号：PCT/US2016/062394
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VLERICK, David , KASTELEIN, Robert A.
发明人： BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VLERICK, David , KASTELEIN, Robert A.
IPC分类号： C07K16/28 , C07K16/18
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.

4. 发明申请

WO2017087587A1 PD1/CTLA4 Binders 审中-公开
标题翻译： PD1 / CTLA4粘合剂
公开(公告)号：WO2017087587A1
公开(公告)日：2017-05-26
申请号：PCT/US2016/062391
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , PUNNONEN, Juha , BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn , VLERICK, David
发明人： PUNNONEN, Juha , BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn , VLERICK, David
IPC分类号： C07K16/18 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/18 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/76 , C07K2317/92 , Y02A50/403
摘要： The present invention provides multispecific molecules, e.g. , comprising more than one ISVD or Nanobody, that bind to PD1 and CTLA4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
摘要翻译：本发明提供了多特异性分子，例如包含与PD1和CTLA4结合的超过一种ISVD或纳米抗体。已经对这些分子进行了工程改造，从而降低施用这种分子的受试者体内预先存在的抗体的结合发生率。提供了增加免疫应答，治疗癌症和/或用这些分子治疗感染性疾病的方法。

5. 发明申请

WO2017087589A2 PD1 AND/OR LAG3 BINDERS 审中-公开
标题翻译： PD1和/或LAG3结合剂
公开(公告)号：WO2017087589A2
公开(公告)日：2017-05-26
申请号：PCT/US2016/062394
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VLERICK, David
发明人： BOWMAN, Edward , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VLERICK, David
IPC分类号： C07K16/28 , C07K16/18
CPC分类号： C07K16/2803 , A61K39/3955 , A61K45/06 , C07K16/18 , C07K16/2818 , C07K16/468 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/76 , C07K2317/92
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to PD1 and LAG3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
摘要翻译：本发明提供结合PD1和LAG3以及任选结合人血清白蛋白的分子，例如ISVD和纳米抗体。已经对这些分子进行了工程改造，从而降低施用这种分子的受试者体内预先存在的抗体的结合发生率。提供了增加免疫应答，治疗癌症和/或用这些分子治疗感染性疾病的方法。

6. 发明申请

WO2017087588A1 CTLA4 BINDERS 审中-公开
公开(公告)号：WO2017087588A1
公开(公告)日：2017-05-26
申请号：PCT/US2016/062393
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , PUNNONEN, Juha , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn
发明人： PUNNONEN, Juha , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn
IPC分类号： C07K16/18 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K14/765 , C07K16/18 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/76 , C07K2317/92 , C07K2319/31
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
摘要翻译：本发明提供了结合CTLA4或人血清白蛋白的分子，例如ISVD和纳米抗体。已经对这些分子进行了工程改造，从而降低施用这种分子的受试者体内预先存在的抗体的结合发生率。提供了增加免疫应答，治疗癌症和/或用这些分子治疗感染性疾病的方法。

7. 发明申请

WO2003046008A1 THERAPEUTIC USE OF ANTIBODIES AND FRAGMENTS THEREOF BINDING PRIMATE IFN-GAMMA 审中-公开
标题翻译：抗体及其结合治疗原始IFN-GAMMA的片段的治疗应用
公开(公告)号：WO2003046008A1
公开(公告)日：2003-06-05
申请号：PCT/EP2002/013358
申请日：2002-11-27
申请人： INNOGENETICS N.V. , LORRÉ, Katrien , BUYSE, Marie-Ange
发明人： LORRÉ, Katrien , BUYSE, Marie-Ange
IPC分类号： C07K16/24
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24
摘要： The present invention relates to the therapeutic use of molecules which bind and neutralize IFN-γ in primates. More specifically, the present invention relates to the use of an anti-primate IFN-γ antibody for preventing or treating diseases wherein IFN-γ is pathogenic. The present invention further relates to a pharmaceutical composition comprising the anti-primate IFN-γ antibody D9D10 for preventing or treating pathological reactions caused by IFN-γ.
摘要翻译：本发明涉及在灵长类动物中结合和中和IFN-of的分子的治疗用途。更具体地，本发明涉及抗灵长类动物IFN-ϝ抗体用于预防或治疗其中IFN-ϝ是致病性的疾病的用途。本发明还涉及包含用于预防或治疗由IFN-reactions引起的病理学反应的抗灵长类动物IFN-ϝ抗体D9D10的药物组合物。

8. 发明申请

WO2012131078A1 BISPECIFIC BINDING MOLECULES BINDING TO VEGF AND ANG2 审中-公开
标题翻译：双向结合分子与VEGF和ANG2结合
公开(公告)号：WO2012131078A1
公开(公告)日：2012-10-04
申请号：PCT/EP2012/055901
申请日：2012-03-30
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , GSCHWIND, Andreas , OTT, Rene Georg , BOUCNEAU, Joachim , BUYSE, Marie-Ange , DEPLA, Erik
发明人： GSCHWIND, Andreas , OTT, Rene Georg , BOUCNEAU, Joachim , BUYSE, Marie-Ange , DEPLA, Erik
IPC分类号： C07K16/22 , C07K16/26
CPC分类号： C07K16/468 , C07K16/18 , C07K16/22 , C07K2317/22 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/62 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2- mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
摘要翻译：结合VEGF和Ang2的双歧杆菌结合分子，优选以免疫球蛋白单可变结构域（如VHH和结构域抗体）的形式，含有它们的药物组合物及其在治疗与VEGF-和/或Ang2-介导的相关疾病中的用途公开了对血管发生的作用。此外，还描述了编码双特异性结合分子的核酸，宿主细胞及其制备方法。

9. 发明申请

WO2008107400A1 HCV POLYEPITOPE CONSTRUCT AND USES THEREOF 审中-公开
标题翻译： HCV多肽构建及其用途
公开(公告)号：WO2008107400A1
公开(公告)日：2008-09-12
申请号：PCT/EP2008/052517
申请日：2008-02-29
申请人： GENIMMUNE N.V. , PHARMEXA INC. , BUYSE, Marie-Ange , BAKER, Denise , VERHEYDEN, Gert
发明人： BUYSE, Marie-Ange , BAKER, Denise , VERHEYDEN, Gert
IPC分类号： C07K14/18 , A61K39/29
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/53 , A61K2039/545 , C07K14/005 , C07K2319/00 , C12N2770/24222 , C12N2770/24234
摘要： The present invention is directed to a HCV polyepitope construct and the use thereof for the prevention and/or treatment of HCV infection.
摘要翻译：本发明涉及HCV多表位构建体及其用于预防和/或治疗HCV感染的用途。

10. 发明申请

WO2012131076A1 BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 审中-公开
标题翻译： BISPECIFIC BINDING分子结合Dll4和Ang2
公开(公告)号：WO2012131076A1
公开(公告)日：2012-10-04
申请号：PCT/EP2012/055897
申请日：2012-03-30
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , GSCHWIND, Andreas , OTT, Rene Georg , BOUCNEAU, Joachim , BUYSE, Marie-Ange , DEPLA, Erik
发明人： GSCHWIND, Andreas , OTT, Rene Georg , BOUCNEAU, Joachim , BUYSE, Marie-Ange , DEPLA, Erik
IPC分类号： C07K16/22 , C07K16/18
CPC分类号： C07K16/468 , C07K16/18 , C07K16/22 , C07K2317/22 , C07K2317/31 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/569 , C07K2317/74 , C07K2317/76 , C07K2317/90 , C07K2317/92
摘要： Bispecifc binding molecules binding to both Dll4 and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that areassociated with Dll4-and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.
摘要翻译：结合Dll4和Ang2的双歧杆菌结合分子，优选以免疫球蛋白单可变结构域（如VHH和结构域抗体）的形式，含有它们的药物组合物及其在治疗与Dll4和/或Ang2介导的作用相关的疾病中的用途公开了血管发生。此外，还描述了编码双特异性结合分子的核酸，宿主细胞及其制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式